BioSyent (RX.V) Azione Prezzo
BioSyent Prezzo
Il fatturato è cresciuto a un tasso composto del 19,3% annuo negli ultimi 19 anni, raggiungendo 43,05 Mio. CAD. L'utile per azione è cresciuto del 18,6% all'anno negli ultimi 19 anni. Il margine netto di BioSyent si attesta al 20,9%, in calo rispetto al 21,9% di alcuni anni fa. BioSyent offre attualmente un rendimento da dividendo di circa il 1,18%. Il payout ratio è pari a circa il 25% degli utili. Il dividendo è cresciuto del 71,0% all'anno negli ultimi 3 anni. Gli analisti fissano un target di prezzo mediano di 16,83 CAD, ovvero il 0,5% sotto il prezzo attuale. Su 7 analisti, 6 valutano il titolo come acquisto — nel complesso un consenso Acquistare.
BioSyent Prezzo delle azioni
BioSyent Azione e analisi azionaria
Domande frequenti sull'azione BioSyent
The business model of Biosyent Inc is focused on acquiring or in-licensing pharmaceutical and healthcare products. The company identifies niche markets with unmet medical needs and seeks regulatory approval to provide branded pharmaceuticals or health products that address those needs. Biosyent Inc aims to improve patient outcomes by offering innovative and effective treatment options in areas such as cardiovascular health, dermatology, neurology, and pediatrics. By partnering with established companies or acquiring the rights to specific products, Biosyent Inc brings affordable and quality medicines to market, providing patients with improved access to vital healthcare solutions.
Biosyent Inc is primarily active in the pharmaceutical and healthcare industries.
The main competitors of Biosyent Inc in the market include pharmaceutical companies like Apotex Inc, Teva Pharmaceutical Industries Ltd, and Mylan N.V.
Biosyent Inc is a pharmaceutical company based in Canada. It was founded in 2004 and has since become a leader in the specialty pharmaceutical industry. The company focuses on acquiring or in-licensing niche pharmaceutical products, with a goal to provide reliable and effective therapeutic options to patients and healthcare professionals. Biosyent Inc has a successful track record of commercializing pharmaceutical products and has established a strong presence in the Canadian market. With a commitment to high-quality medications, Biosyent Inc continuously strives to meet the evolving healthcare needs of the population.
Biosyent Inc has achieved significant milestones since its inception. The company has successfully launched and commercialized multiple pharmaceutical and healthcare products in Canada. This includes obtaining regulatory approvals for important drugs, expanding their product portfolio, and establishing strategic partnerships with global pharmaceutical companies. Biosyent Inc has also demonstrated consistent revenue growth and increased market share, highlighting its strong performance in the industry. With their commitment to innovation and delivering high-quality products, Biosyent Inc continues to contribute to the advancement of healthcare and pharmaceuticals.
Biosyent Inc is primarily present in Canada and the United States.
Biosyent Inc is a pharmaceutical company that values innovation, sustainability, and customer-centricity. Their corporate philosophy revolves around providing high-quality, niche pharmaceutical products to meet the evolving healthcare needs of patients. With a focus on sourcing and licensing unique product opportunities, Biosyent Inc has built a strong reputation as a reliable partner within the healthcare industry. By utilizing their expertise in regulatory affairs and product commercialization, Biosyent Inc strives to improve patient outcomes while delivering value to their shareholders.
Gli analisti fissano attualmente un prezzo obiettivo medio di 16,83 CAD per l’azione BioSyent (mediana: 16,83 CAD), pari a -0,5 % rispetto all’ultimo prezzo. Il consenso si basa su 7 giudizi di analisti.
7 analisti valutano attualmente l’azione BioSyent: 6 raccomandano l’acquisto, 1 la tenuta e 0 la vendita. Per il 2026 gli analisti si aspettano per BioSyent ricavi pari a 73,20 Mio. CAD e un utile per azione di 1,05 CAD.
Convertita al tasso di cambio attuale, l’azione BioSyent quota 10,60 EUR (16,92 CAD).
L’azione BioSyent (RX.V) è quotata su 2 borse, tra cui: Toronto (RX.V).
Biosyent Inc is a pharmaceutical company headquartered in Canada that focuses on the development, marketing, and distribution of innovative products. The company specializes in medications in the areas of dermatology, gastroenterology, urology, and pain management. The business strategy of Biosyent Inc is to bring new products to the market that are needed by the growing number of patients and healthcare providers. In addition, the company also produces generics, which it offers at lower costs than the originals. Biosyent Inc aims to improve the lives of patients through better healthcare solutions. The company is active in various regions and works with partners in Canada, the US, and Europe. Through targeted investments and marketing initiatives, Biosyent Inc has managed to expand its reach and diversify its offerings. The company collaborates closely with physicians, pharmacies, and customers to tailor its offerings to their needs. In the field of dermatology, the company offers preparations for acne, eczema, psoriasis, and other skin problems. In gastroenterology, Biosyent Inc has developed medications that can be used to treat gastrointestinal diseases such as inflammatory bowel disease, Crohn's disease, and ulcerative colitis. In urology, the company offers a solution for erectile dysfunction, and in pain management, it provides effective opioid antagonists in the form of nasal sprays and sublingual tablets. In addition to pharmaceutical products, Biosyent Inc also offers diagnostics and a solution for measuring urine flow. To further improve its products, the company also invests in researching new technologies and therapy forms. The company has a strong research and development department that works closely with the marketing and sales departments. Biosyent Inc strategically invests in the search for new active ingredients and solutions to continue offering its customers innovative products. Furthermore, the company works on optimizing its production processes and increasing its efficiency. The divisions of Biosyent Inc include: - Dermatology - Gastroenterology - Urology - Pain management Biosyent Inc. focuses on diversifying its offerings and producing innovative products that meet the needs of patients. Through the use of new technologies and procedures, the company aims to continue growing and strengthening its position in the market.
Il attesa fatturato di BioSyent ammonta a 73,20 Mio. CAD. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il attesa profitto di BioSyent ammonta a 11,81 Mio. CAD. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di BioSyent è attualmente 16,14. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione BioSyent.
Il rapporto prezzo/fatturato (P/S) di BioSyent è attualmente 2,60. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione BioSyent.
Il Quality Score AlleAktien per BioSyent è 8/10.
L'ISIN di BioSyent è CA0906901081. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di BioSyent è A1J6DY. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di BioSyent è RX.V. Con questo simbolo di borsa vengono negoziate le azioni BioSyent in borsa.
Azione BioSyent
Gruppo di pari di BioSyent
BioSyent Ticker
BioSyent FIGI
Altre metriche e analisi di BioSyent in Deep Dive.
La nostra analisi azionaria dell'azione BioSyent include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di BioSyent. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: